Ventyx Biosciences Inc (VTYX NASDAQ) stock market data APIs
$2.8291
-0.4(-14.1%)
as of July 10, 2025
Try our APIs with
free plan!
Ventyx Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Prev. Close
2.8291
Open
2.434
High
2.8907
Low
2.4292
52 wk Range
0.783-3.39
Market Cap
171 M
Shares Outstanding
71 161 K
EPS
-0.39
Beta
0.85
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ventyx Biosciences Inc data using free add-ons & libraries
Get Ventyx Biosciences Inc Fundamental Data
Ventyx Biosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -136 483 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-05
- EPS/Forecast: -0.69
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ventyx Biosciences Inc News
New
Sight Sciences Leads The Pack Of 3 Promising Penny Stocks
The United States market has remained flat over the past week but is up 11% over the past year, with earnings projected to grow by 15% annually. Though the term 'penny stock' might sound like a relic ...
Ventyx says Parkinson’s disease drug hit main goal in small mid-stage trial
[Parkinsons Disease Torn Paper Concept] IvelinRadkov Ventyx Biosciences (NASDAQ:VTYX [https://seekingalpha.com/symbol/VTYX]) announced Tuesday that a small mid-stage trial for VTX3232, its experiment...
Ventyx reports positive Phase 2a results for Parkinson's drug
SAN DIEGO - Ventyx Biosciences, Inc. (NASDAQ:VTYX), a clinical-stage biotech company with a market capitalization of $181 million, announced Tuesday that its Phase 2a study of VTX3232, an oral NLRP3 i...
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease
The study met its primary goal of establishing safety and tolerability of VTX3232 in patients with early-stage Parkinson’s disease CSF and plasma exposures reinforce VTX3232’s potential as a once...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
